Terms: = Germ cell tumor AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
57 results:
1. Combined PD-1, BRAF and MEK inhibition in BRAF
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
2. The diagnostic and prognostic potential of the egfr/MUC4/MMP9 axis in glioma patients.
Quesnel A; Coles N; Polvikoski TM; Karagiannis GS; Angione C; Islam M; Khundakar AA; Filippou PS
Sci Rep; 2022 Nov; 12(1):19868. PubMed ID: 36400876
[TBL] [Abstract] [Full Text] [Related]
3. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
[TBL] [Abstract] [Full Text] [Related]
4. High Expression of the Lysosomal Protease Cathepsin D Confers Better Prognosis in Neuroblastoma Patients by Contrasting EGF-Induced Neuroblastoma cell Growth.
Secomandi E; Salwa A; Vidoni C; Ferraresi A; Follo C; Isidoro C
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563171
[TBL] [Abstract] [Full Text] [Related]
5. Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract] [Full Text] [Related]
6. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract] [Full Text] [Related]
8. clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract] [Full Text] [Related]
9. SEL1L plays a major role in human malignant gliomas.
Mellai M; Annovazzi L; Boldorini R; Bertero L; Cassoni P; De Blasio P; Biunno I; Schiffer D
J Pathol Clin Res; 2020 Jan; 6(1):17-29. PubMed ID: 31111685
[TBL] [Abstract] [Full Text] [Related]
10. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - a meta-analysis.
Vuong HG; Tran TTK; Ngo HTT; Pham TQ; Nakazawa T; Fung KM; Hassell L; Katoh R; Kondo T
Eur J Neurol; 2019 Mar; 26(3):379-387. PubMed ID: 30298540
[TBL] [Abstract] [Full Text] [Related]
12. Somatic aberrations of BRCA1 gene are associated with ALDH1, egfr, and tumor progression in prostate cancer.
Omari A; Nastały P; Stoupiec S; Bałabas A; Dąbrowska M; Bielińska B; Huss S; Pantel K; Semjonow A; Eltze E; Brandt B; Bednarz-Knoll N
Int J Cancer; 2019 Feb; 144(3):607-614. PubMed ID: 30265376
[TBL] [Abstract] [Full Text] [Related]
13. Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.
Fahy AS; Roberts A; Nasr A; Irwin MS; Gerstle JT
J Pediatr Surg; 2019 Aug; 54(8):1632-1637. PubMed ID: 30029845
[TBL] [Abstract] [Full Text] [Related]
14. High expression of Bruton's tyrosine kinase (BTK) is required for egfr-induced NF-κB activation and predicts poor prognosis in human glioma.
Yue C; Niu M; Shan QQ; Zhou T; Tu Y; Xie P; Hua L; Yu R; Liu X
J Exp Clin Cancer Res; 2017 Sep; 36(1):132. PubMed ID: 28946903
[TBL] [Abstract] [Full Text] [Related]
15. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
[TBL] [Abstract] [Full Text] [Related]
16. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of egfr and PTEN: new opportunities for selected targeted therapies.
Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of TIP30 inhibits the growth and invasion of glioma cells.
Hu Y; Chen F; Liu F; Liu X; Huang N; Cai X; Sun Y; Li A; Luo R
Mol Med Rep; 2016 Jan; 13(1):605-12. PubMed ID: 26718891
[TBL] [Abstract] [Full Text] [Related]
18. Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.
Khan FH; Pandian V; Ramraj S; Aravindan S; Herman TS; Aravindan N
BMC Genomics; 2015 Jul; 16(1):501. PubMed ID: 26148557
[TBL] [Abstract] [Full Text] [Related]
19. High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma.
Meng D; Chen Y; Yun D; Zhao Y; Wang J; Xu T; Li X; Wang Y; Yuan L; Sun R; Song X; Huai C; Hu L; Yang S; Min T; Chen J; Chen H; Lu D
Oncotarget; 2015 Mar; 6(7):4901-19. PubMed ID: 25669971
[TBL] [Abstract] [Full Text] [Related]
20. Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.
Conroy S; Kruyt FA; Joseph JV; Balasubramaniyan V; Bhat KP; Wagemakers M; Enting RH; Walenkamp AM; den Dunnen WF
PLoS One; 2014; 9(12):e115687. PubMed ID: 25546404
[TBL] [Abstract] [Full Text] [Related]
[Next]
